Trial · NCT03865407

Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

NCT03865407, Phase 2, Terminated, Virginia Commonwealth University; results first posted 2021-05-27

3 sourcestrials-2026-11-12-0.4.0

Cite this record

ConductScience Library. Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease. Trials, record NCT03865407. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03865407

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease
NCT number: NCT03865407
Status: Terminated
Phases: Phase 2
Enrollment: 17 participants, actual
Lead sponsor: Virginia Commonwealth University
Conditions: Hyperuricemia, Chronic Kidney Diseases
Interventions: Allopurinol
First posted: 2019-03-06
Last updated: 2021-05-27
Results first posted: 2021-05-27

Source ClinicalTrials.gov

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	eGFR Change	The difference in Cystatin C eGFR between baseline and 6 months will be measured	Change in Cys-C eGFR over time
Primary	eGFR Change	The difference in Creatinine eGFR between baseline and 6 months will be measured	Change in Creatinine eGFR over time
Secondary	Serum Uric Acid Change	The difference in Serum Uric Acid between baseline and 6 months will be measured	Change in Serum Uric Acid
Secondary	Systolic Blood Pressure	The difference in clinic systolic blood pressure between baseline and 6 months will be measured	Change in systolic blood pressure
Secondary	Diastolic Blood Pressure	The difference in clinic diastolic blood pressure between baseline and 6 months will be measured	Change in diastolic blood pressure
Other	Serum High Sensitivity C-reactive Protein (Hs-CRP)	Serum hs-CRP will be measured at baseline and 6 months	Compare the mean difference of serum hs-CRP from baseline to 6 months between groups
Other	Interleukin 18	Serum interleukin 18 will be measured at baseline, 3 months, and 6 months	Change in interleukin 18
Other	Serum Nlrp3	Serum Nlrp3 will be measured at baseline, 3 months, and 6 months	Change in serum Nlrp3
Other	Urine Neutrophil Gelatinase-associated Lipocalin (NGAL)	Urine NGAL will be measured at baseline, 3 months, and 6 months	Change in urine NGAL
Other	Urine Endothelin-1 (ET-1)	Urine ET-1 will be measured at baseline, 3 months, and 6 months	Change in urine ET-1

1 to 10 of 12Source ClinicalTrials.gov

See all 12 registered outcomes

Outcomes12

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	eGFR Change	The difference in Cystatin C eGFR between baseline and 6 months will be measured		ml/min/1.73m^2	MEAN
PRIMARY	eGFR Change	The difference in Creatinine eGFR between baseline and 6 months will be measured		ml/min/1.73m^2	MEAN
SECONDARY	Serum Uric Acid Change	The difference in Serum Uric Acid between baseline and 6 months will be measured		mg/dl	MEAN
SECONDARY	Systolic Blood Pressure	The difference in clinic systolic blood pressure between baseline and 6 months will be measured	Follow up blood pressure data was not collected from one participant in the treatment group	mmHg	MEAN
SECONDARY	Diastolic Blood Pressure	The difference in clinic diastolic blood pressure between baseline and 6 months will be measured	Follow up blood pressure data was not collected from one participant in the treatment group	mmHg	MEAN
OTHER_PRE_SPECIFIED	Serum High Sensitivity C-reactive Protein (Hs-CRP)	Serum hs-CRP will be measured at baseline and 6 months		mg/dL	MEAN
OTHER_PRE_SPECIFIED	Interleukin 18	Serum interleukin 18 will be measured at baseline, 3 months, and 6 months
OTHER_PRE_SPECIFIED	Serum Nlrp3	Serum Nlrp3 will be measured at baseline, 3 months, and 6 months
OTHER_PRE_SPECIFIED	Urine Neutrophil Gelatinase-associated Lipocalin (NGAL)	Urine NGAL will be measured at baseline, 3 months, and 6 months
OTHER_PRE_SPECIFIED	Urine Endothelin-1 (ET-1)	Urine ET-1 will be measured at baseline, 3 months, and 6 months

1 to 10 of 12Source ClinicalTrials.gov

See all 12 outcomes

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
eGFR Change	Allopurinol	3.14	Standard Deviation 3.716	ml/min/1.73m^2
eGFR Change	Standard of Care Control	-0.29	Standard Deviation 5.251	ml/min/1.73m^2
eGFR Change	Allopurinol	3.86	Standard Deviation 7.798	ml/min/1.73m^2
eGFR Change	Standard of Care Control	0	Standard Deviation 3.857	ml/min/1.73m^2
Serum Uric Acid Change	Allopurinol	-3.33	Standard Deviation 0.996	mg/dl
Serum Uric Acid Change	Standard of Care Control	-0.46	Standard Deviation 0.964	mg/dl
Systolic Blood Pressure	Allopurinol	-6.5	Standard Deviation 13.126	mmHg
Systolic Blood Pressure	Standard of Care Control	2.29	Standard Deviation 6.264	mmHg
Diastolic Blood Pressure	Allopurinol	-7.33	Standard Deviation 6.29	mmHg
Diastolic Blood Pressure	Standard of Care Control	3.983	Standard Deviation 7.543	mmHg

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Allopurinol	10
Overall Study	STARTED	Standard of Care Control	7
Overall Study	COMPLETED	Allopurinol	7
Overall Study	COMPLETED	Standard of Care Control	7
Overall Study	NOT COMPLETED	Allopurinol	3
Overall Study	NOT COMPLETED	Standard of Care Control	0

Source ClinicalTrials.gov

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
serious	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome	Immune system disorders	Allopurinol	1	7	1
serious	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome	Immune system disorders	Standard of Care Control	0	7	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Allopurinol	0	7
Total, all-cause mortality	Standard of Care Control	0	7
Total, other adverse events	Allopurinol	0	7
Total, other adverse events	Standard of Care Control	0	7
Total, serious adverse events	Allopurinol	1	7
Total, serious adverse events	Standard of Care Control	0	7

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Allopurinol vs Standard of Care Control: deaths from any cause	Trial comparisons
Allopurinol vs Standard of Care Control: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release: trials-2026-11-12-0.4.0
Release manifest SHA-256: 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture: 2026-11-12
Results copy, AACT: 2026-03-23
NIH clinical studies file: 2026-11-13

Source ClinicalTrials.gov

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03865407

GET https://conductscience.org/api/trials/v1/NCT03865407/registered

API reference For AI assistants